Metabolic marker for arsenic toxicity resistance of mucopolysaccharide of swimming bladder as well as screening method and application of metabolic marker
Through non-targeted metabolomic screening, the metabolic markers regulated by fish bladder mucopolysaccharide in mice were determined, which solved the problem of how fish bladder mucopolysaccharide improves arsenic toxicity, achieved effective prevention and targeted regulation of arsenic toxicity, and provided Reference for dietary supplements and drug development.
Patent Information
- Application Number
- CN202411168072.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has not yet clarified how fish bladder mucopolysaccharide improves arsenic toxicity in metabolic form, and insufficient methods for diagnosis and prevention of early arsenic toxicity.
Non-targeted metabolomics method was used to screen the metabolic markers of anti-arsenic toxicity of mucopolysaccharides in fish bladder, including L-aspartic acid, D-aspartic acid and pyruvate, and mice were tested by gavage and analyzed in their feces. Differential metabolites, combined with KEGG enrichment analysis and topological analysis, determine the metabolic pathway regulated by mucopolysaccharides in fish bladder to alleviate arsenic-induced metabolic disorders.
Rapid and efficient screening of metabolic markers of anti-arsenic toxicity of mucopolysaccharides in fish bladder provides dietary strategies and targeted regulatory means to improve arsenic toxicity, significantly improves arsenic-induced metabolic disorders, and provides a reference for anti-arsenic toxic drug targets.
Smart Images

Figure CN118914571A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and relates to metabolic markers of fish swim bladder mucopolysaccharide against arsenic toxicity, and a screening method and application thereof. Background Art
[0002] Arsenic is a metalloid element widely found in nature and is a type of environmental pollutant with carcinogenic risks. Arsenic has damaging effects on multiple organs such as the liver, kidneys, intestines and brain. It is often ingested by the human body in the form of drinking water, breathing and bioaccumulation, and is mostly chronic and subchronic toxic. Therefore, early diagnosis of arsenic toxicity and effective exploration of ways to prevent arsenic toxicity are conducive to preventing the harm of arsenic to human health.
[0003] Metabolomics is a discipline that conducts qualitative and quantitative analysis of all low-molecular-weight metabolites of a certain organism or cell during a specific physiological period. It is often used in related fields such as disease diagnosis, nutritional science, toxicology, and environmental science. In the field of disease diagnosis and prevention, discovering metabolite markers is of great significance for personalized drug treatment and precise regulation of disease processes. Metabolomics can be divided into targeted and non-targeted metabolomics. Non-targeted metabolomics is a research method that conducts a systematic and comprehensive analysis of the entire metabolome to find differential metabolites. Therefore, it is often used in the screening of metabolite markers to provide ideas and directions for seeking disease targets.
[0004] Fish bladder is a substance that can be used as both medicine and food. The prior art CN117018020A discloses that its active ingredient, fish bladder mucopolysaccharide, has the effect of slowing down arsenic-induced intestinal damage, showing its application prospects in improving arsenic toxicity. Fish bladder mucopolysaccharide is a macromolecular polysaccharide that is shown not to be absorbed and utilized in the upper digestive tract, but to be utilized by intestinal flora in the lower digestive tract to produce beneficial metabolites to exert its functional characteristics, and has the potential of being a prebiotic. However, how it works to improve arsenic toxicity in the form of metabolism is not yet clear.
[0005] The present invention uses the fish bladder-derived heparin glycosaminoglycans prepared by using the fish bladder-derived heparin glycosaminoglycans with the publication number CN112107590A on September 14, 2021 in the preparation of angiogenesis inhibitors to screen metabolic markers for resistance to arsenic toxicity. Summary of the invention
[0006] The purpose of the present invention is to explore biomarkers of fish bladder mucopolysaccharide resistance to arsenic toxicity in a non-targeted metabolomics manner for the prevention of early arsenic poisoning, and to provide dietary strategies and precise targeted regulation for improving arsenic toxicity. Based on the above objectives, the present invention provides a metabolic marker of fish bladder mucopolysaccharide resistance to arsenic toxicity and its screening method and application.
[0007] In a first aspect, the present invention provides a metabolic marker of fish bladder mucopolysaccharide against arsenic toxicity, wherein the fish bladder mucopolysaccharide is a chondroitin sulfate A analogue containing a structural unit of →4GlcUAβ1→3GalNAc(4S)β1→main chain; The arsenic toxicity is derived from the metabolic disorder induced by arsenic; The metabolic markers of fish swim bladder mucopolysaccharide against arsenic toxicity include L-aspartic acid, D-aspartic acid and pyruvic acid.
[0008] Furthermore, the present invention obtains biomarkers of arsenic toxicity by gavaging test mice with sodium arsenite solution, collecting feces of the test mice, and analyzing differential metabolites of arsenic-induced test mice. The biomarkers of arsenic toxicity are at least one of taurine, thiamine, nicotinic acid mononucleotide compounds, and nicotinamide adenine dinucleotide.
[0009] In a second aspect, the present invention provides a method for screening metabolic markers of fish maw mucopolysaccharide resistance to arsenic toxicity, comprising: collecting feces of mice subjected to arsenic-induced test by gavage with fish maw mucopolysaccharide, and after the feces are subjected to ultra-high performance liquid chromatography-mass spectrometry analysis for differential metabolites, attributing metabolic pathways based on the differential metabolites and analyzing metabolic markers of fish maw mucopolysaccharide resistance to arsenic toxicity.
[0010] Furthermore, in the present invention, the experimental mice are gavaged with 50-200 mg / kg of fish maw mucopolysaccharide solution in the morning and 5 mg / kg of sodium arsenite solution in the afternoon.
[0011] Preferably, the dosage of fish swim bladder mucopolysaccharide administered intragastrically is 100 mg / kg.
[0012] Furthermore, the present invention found through analysis of differential metabolites in feces of mice subjected to arsenic-induced test after gavage with fish bladder mucopolysaccharide that fish bladder mucopolysaccharide can regulate differential metabolites to alleviate metabolic disorders induced by arsenic, specifically including: regulating at least one of lipids, lipoid substances, organic acids, and organic acid derivatives.
[0013] Specifically, the differential metabolites are mainly at least one of 2-hydroxy-3-methylbutyric acid, ginsenotriol, and sedoheptulose.
[0014] Furthermore, the present invention combines the Kyoto Encyclopedia of Genes and Genomes KEGG Pathway database to annotate differential metabolites, performs KEGG enrichment analysis on the metabolic pathways where the differential metabolites are located, and obtains a KEGG enriched pathway, wherein the KEGG enriched pathway is at least one of amino acids, carbohydrates, and lipids.
[0015] Furthermore, the present invention performs topological analysis on the KEGG enrichment pathway to obtain a key metabolic pathway, wherein the key metabolic pathway is at least one of alanine, aspartic acid, and glutamate.
[0016] In a third aspect, the present invention provides a use of a metabolic marker of fish swim bladder mucopolysaccharide against arsenic toxicity in the preparation of a dietary supplement for preventing arsenic toxicity.
[0017] In a fourth aspect, the present invention provides an application of a metabolic marker of fish swim bladder mucopolysaccharide against arsenic toxicity in the preparation of drug targets for improving arsenic poisoning.
[0018] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages: (1) The fish maw mucopolysaccharide provided by the present invention exhibits excellent effects on improving differential metabolites, KEGG enriched pathways and key pathways in the process of resisting arsenic toxicity.
[0019] (2) The screening of anti-arsenic toxicity metabolites of fish bladder mucopolysaccharide provided by the present invention is rapid and efficient, and can provide a reference for the development of dietary supplements and drugs using fish bladder mucopolysaccharide as an additive to alleviate arsenic toxicity.
[0020] (3) The metabolites of L-aspartic acid, D-aspartic acid and pyruvic acid obtained by screening the metabolic markers of fish swim bladder mucopolysaccharide for anti-arsenic toxicity provided by the present invention can be used for the subsequent exploration of anti-arsenic toxicity drug targets. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The results of screening metabolic markers for arsenic-exposed mice are shown in Figure 1. A is the OPLS-DA score of the OPLS-DA model; B is the match chart of the top ten up-regulated and down-regulated differential metabolites; C is the KEGG enrichment pathway classification chart; D is the bubble chart of differential metabolic pathways; * indicates significant difference.
[0022] Figure 2 The results of the determination of the effects of fish bladder mucopolysaccharide on the differential metabolites of arsenic-exposed mice. A is a match chart of the top ten differential metabolites up-regulated and down-regulated between the model group and the low-dose fish bladder mucopolysaccharide; B is a match chart of the top ten differential metabolites up-regulated and down-regulated between the model group and the medium-dose fish bladder mucopolysaccharide; C is a match chart of the top ten differential metabolites up-regulated and down-regulated between the model group and the high-dose fish bladder mucopolysaccharide; * indicates significant difference.
[0023] Figure 3 The results of the determination of KEGG enrichment pathways of fish bladder mucopolysaccharides in arsenic-exposed mice. A is the classification diagram of KEGG enrichment pathways of model group and low-dose fish bladder mucopolysaccharides; B is the classification diagram of KEGG enrichment pathways of model group and medium-dose fish bladder mucopolysaccharides; C is the classification diagram of KEGG enrichment pathways of model group and high-dose fish bladder mucopolysaccharides.
[0024] Figure 4The results of the determination of the key metabolic pathways of fish bladder mucopolysaccharide on arsenic-exposed mice. A is the bubble diagram of the differential metabolic pathways between the model group and the low-dose fish bladder mucopolysaccharide; B is the bubble diagram of the differential metabolic pathways between the model group and the medium-dose fish bladder mucopolysaccharide; C is the bubble diagram of the differential metabolic pathways between the model group and the high-dose fish bladder mucopolysaccharide. DETAILED DESCRIPTION
[0025] The technical scheme of the present invention is described below in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in each embodiment are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.
[0026] Example 1 This example provides an animal experiment for screening metabolic markers in arsenic-exposed mice.
[0027] 1. Establish the test model Twenty-four male SPF-grade C57BL / 6J mice (18±2g, 7 weeks old) were randomly divided into two groups (control group and model group), with 12 mice in each group. The control group was gavaged with 0.1mL / 10g normal saline in the morning and afternoon. The model group was gavaged with 0.1mL / 10g normal saline in the morning and 5mg / kg sodium arsenite solution in the afternoon. After the gavage of each group of mice every day, the mice in each group were free to eat, and the control group and the model group were given continuous gavage for 38 days. Fresh feces were collected after the last gavage.
[0028] 2. Non-targeted metabolomics analysis of mouse feces (1) Extraction of metabolites Weigh 25 mg of mouse feces sample and add 500 μL of extract containing methanol:acetonitrile:water = 2:2:1 (V / V) and isotope-labeled internal standard mixture. After grinding for 4 minutes, place in an ice water bath for ultrasonic treatment for 15 minutes (5 minutes / time). Stand at -40℃ for 1 hour to remove proteins and fully extract metabolites. Centrifuge at 4℃ and 12000rpm / min for 15 minutes, take the supernatant and put it in an injection bottle for metabolite detection by ultra-high performance liquid chromatography-mass spectrometry.
[0029] (2) Separation and identification of metabolites The metabolites were determined by ultra-high performance liquid chromatography-mass spectrometry, with an injection volume of 2 μL, a column temperature of 30°C, and a flow rate of 0.5 mL / min. Phase A was an aqueous phase containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia, and phase B was acetonitrile. The mass spectrometry conditions were as follows: sheath gas flow rate of 50 Arb, auxiliary gas flow rate of 15 Arb, capillary temperature of 320°C, full MS resolution of 60,000, and MS / MS resolution of 15,000.
[0030] (3) Metabolic data analysis The original data were processed by the R package (independently written by Shanghai Baiqu Biomedical Technology Co., Ltd.) for peak processing and integration. Then, qualified data were obtained by filtering outliers and missing values, filling missing values, and standardizing data, and then matched with the self-built secondary mass spectrometry database of BiotreeDB (V2.1) for material annotation. Orthogonal partial least squares discriminant analysis (OPLS-DA) was performed using Sigma software. Combined with the t-test (t-test) P value <0.5 and the variable projection importance VIP>1 of the first principal component in the OPLS-DA model, significant differential metabolites were screened and visualized. Differential metabolites were annotated in combination with the Kyoto Encyclopedia of Genes and Genomes KEGG Pathway database, and KEGG enrichment analysis was performed based on the results. Finally, the key pathways where the differential metabolites are located were obtained through comprehensive analysis of the pathways where the differential metabolites are located (enrichment analysis and topological analysis).
[0031] 3. Results of screening and determination of metabolic markers in mice with arsenic-induced metabolic disorders The Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) model is a supervised discriminant analysis statistical method used to improve the analytical ability and effectiveness of the model, thereby clarifying the true differences between groups and screening effective differential metabolites. Figure 1 As shown in A, there is an obvious separation in the metabolite composition between the control group and the model group, indicating that arsenic exposure caused metabolite disorder in mice.
[0032] Differential metabolites were obtained under the set screening criteria, and the top ten substances with up- and down-regulated folds were selected, and the change trend was displayed in a matchstick chart. Figure 1 As shown in the B matchstick diagram, compared with the control group, half of the significantly upregulated metabolites in the model group were amino acids, and the significantly downregulated substances were mainly lipids and lipid-like substances and nucleosides. Among them, almost all lipids and lipid-like substances were glycerophospholipids, which may be related to the excessive consumption of lipid substances caused by lipid peroxidation in the body. From the size of the VIP value, it can be seen that the largest changes in these upregulated and downregulated metabolites are valyl-phenylalanine and thiamine.
[0033] Then, we analyzed the pathways related to metabolite enrichment, used the KEGG Pathway database for functional annotation, and classified the annotation results to obtain the KEGG classification diagram. There are a total of 7 primary pathways in the KEGG Pathway module, including metabolic processes, genetic information processing, environmental information processing, etc. The primary pathway also contains secondary and tertiary pathways. Figure 1From the C in the figure, we can see that most of the pathways that changed after arsenic exposure were related to metabolic processes, and a small number were related to environmental information processing, biological systems, and human diseases. From the perspective of metabolic classification, it was found that in addition to the main classification of the organism, Global and overview maps, arsenic exposure mainly affected lipid metabolism, nucleotide metabolism, auxiliary factor and vitamin metabolism, and amino acid metabolism. Among them, linoleic acid metabolism changed most significantly in lipid metabolism. From the perspective of environmental information processing, it can be seen that ABC transporters, which play an important role in transmembrane transport, accounted for the largest proportion of 23.81%. From the perspective of biological systems, arsenic exposure mainly affected the digestive system, endocrine system, and nervous system. Moreover, it can be seen that the digestion and absorption pathways of vitamins and the PPAR signaling pathway changed most significantly in this group comparison. The results of this part show that after arsenic exposure, multiple metabolic pathways of the body will change, and the lipid metabolism and vitamin metabolism of the body will be significantly disrupted.
[0034] Combining enrichment analysis and topological analysis, the key pathways with the highest correlation with metabolite differences were screened out and presented in the form of bubble charts (the size of the area represents the size of the impact factor, and the depth of the color represents the degree of significance). Figure 1 D in the figure shows that after arsenic exposure, six differential pathways with obvious correlations changed. The top three in terms of influencing factors were taurine and hypotaurine metabolism, thiamine metabolism, and niacin and nicotinamide metabolism. Among them, niacin and nicotinamide metabolism was the most significant change after arsenic exposure. By analyzing the differential metabolites in the key pathways, it can be found that taurine, a substance involved in both taurine and hypotaurine metabolism and primary bile acid biosynthesis, was significantly upregulated after arsenic exposure. This substance is closely related to glucose and lipid metabolism. It significantly downregulated thiamine in thiamine metabolism. Thiamine is the most significantly downregulated substance in the differential metabolite analysis. It is a vitamin substance that can effectively eliminate heavy metals. In niacin and nicotinamide metabolism, arsenic exposure significantly downregulated nicotinic acid mononucleotide compounds and upregulated nicotinamide adenine dinucleotide, both of which are closely related to energy metabolism. The results of this part show that the metabolic markers of arsenic-induced metabolic disorder mice are taurine, thiamine, nicotinic acid mononucleotide compounds, and nicotinamide adenine dinucleotide.
[0035] Example 2 This example provides an animal experiment on the screening of metabolic markers of arsenic-induced metabolic disorder mice using fish bladder mucopolysaccharide.
[0036] The preparation method of the fish bladder mucopolysaccharide used in this example is as described in Example 1 of the patent publication number CN112107590A. The fish bladder mucopolysaccharide is a chondroitin sulfate A analogue containing a structural unit of →4GlcUAβ1→3GalNAc(4S)β1→main chain.
[0037] 1. Establish the test model Forty-eight male SPF C57BL / 6J mice (18±2g, 7 weeks old) were randomly divided into 4 groups (model group, fish bladder mucopolysaccharide group, among which the fish bladder mucopolysaccharide group was further divided into low, medium and high dose groups), with 12 mice in each group. The low dose group was gavaged with 50mg / kg, the medium dose group was gavaged with 100mg / kg and the high dose group was gavaged with 200mg / kg. The fish bladder mucopolysaccharide group was gavaged with fish bladder mucopolysaccharide solution in the morning and 5mg / kg sodium arsenite solution in the afternoon according to the gavage dose. The model group was gavaged with 0.1mL / 10g normal saline in the morning and 5mg / kg sodium arsenite solution in the afternoon. After the gavage of each group of mice every day, the mice in each group were free to eat, and the experimental groups (model group, low dose group, medium dose group and high dose group) were given continuous gavage for 38 days. After the last gavage, fresh feces of the mice were collected.
[0038] 2. Non-targeted metabolomics analysis of mouse feces The specific steps of extraction, separation, identification and data analysis of mouse metabolites in this example are the same as those shown in step 2 of Example 1.
[0039] 3. Screening results of metabolic markers of fish swim bladder mucopolysaccharide against arsenic toxicity From the parameters of OPLA-DA in Table 1, we can see that the interpretability of each dose group of fish maw mucopolysaccharide is R 2 The Y score is approximately 1, which indicates that the model is predictive. 2 The scores were all greater than 0.4, indicating that the comparison of the groups was highly interpretable, the model was robust, the differences were large, and it had a certain degree of predictability, indicating that the metabolic analysis model of each group of mice was reasonable and could be further analyzed.
[0040] Table 1 Parameters of the OPLS-DA model in Example 2 of the present invention
[0041] Depend on Figure 2 The differential metabolites matchstick diagram shows that the types and extent of differential metabolites of arsenic-exposed mice after intervention with different doses of fish bladder mucopolysaccharide are different. Figure 2 A) and high-dose group ( Figure 2 Compared with B), there were more metabolites with significant changes in the medium-dose group ( Figure 2B), the VIP values show that the substances with the largest changes in up-regulated and down-regulated substances are 2-hydroxy-3-methylbutyric acid and ginsenotriol, respectively. With the increase in dose, the changes in differential metabolites began to focus on lipids and lipid-like substances and organic acids and their derivatives. In the medium-dose group, the up-regulated differential substances were mostly fatty acids, and the down-regulated substances were mostly glycerophospholipids, indicating that the medium-dose fish bladder mucopolysaccharide promoted the lipid metabolic transformation process in arsenic-exposed mice. In the medium-dose group, the substances with the largest changes in up-regulated and down-regulated substances were hydroxyisocaproic acid and 6-deoxycholesterol, respectively. In the high-dose group, the changes in organic acids and lipids were similar ( Figure 2 C in the figure), among which hydroxyisocaproic acid and proline betaine had the largest changes in the up-regulated and down-regulated substances, respectively. Among them, the common substance that was significantly up-regulated in each dose group of fish bladder mucopolysaccharide was 2-hydroxy-3-methylbutyric acid, and the substances that were significantly down-regulated were ginsenotriol and sedoheptulose. Among them, 2-hydroxy-3-methylbutyric acid was shown to have an important connection with the receptor GPR109A related to the production of short-chain fatty acids, which are beneficial metabolites in the intestine. The results indicate that fish bladder mucopolysaccharides mainly regulate lipids and organic acids in the process of resisting arsenic toxicity, and have an important influence on the production of short-chain fatty acids.
[0042] Figure 3 is the KEGG classification diagram, Figure 3 It can be seen that most of the pathways that changed after the action of fish bladder mucopolysaccharide were related to metabolic processes, among which the top three secondary metabolic processes were amino acid metabolism and carbohydrate metabolism. Figure 3 A) and high doses ( Figure 3 From the perspective of human diseases, fish bladder mucopolysaccharides have a greater impact on cancer-related pathways. From the perspective of biological systems, low-dose fish bladder mucopolysaccharides mainly affect the nervous system, and as the dose increases, they gradually tend to regulate the digestive system. It can be seen that at medium doses ( Figure 3 B) significantly affected protein digestion and absorption and mineral absorption. From the perspective of environmental information processing, it can be seen that there were significant changes in the ABC transporter pathway for membrane transport in the low-dose and medium-dose groups, while the high-dose group tended to significantly affect the cAMP signaling pathway in signal transduction. For genetic information processing, the aminoacyl-tRNA biosynthesis pathway related to translation showed a greater effect in the medium-dose and high-dose groups. This result shows that the action of fish bladder mucopolysaccharides has a more significant effect on amino acid metabolism and carbohydrate metabolism. In addition, D-amino acid metabolism and ABC transporters changed at each dose, and both are the main enrichment pathways for fish bladder mucopolysaccharides to resist arsenic toxicity.
[0043] Depend on Figure 4The bubble diagram of differential metabolic pathways shows that the differential metabolic pathways affected by the action of fish bladder mucopolysaccharide are amino acid metabolism, carbohydrate metabolism, and metabolism of other amino acids. Figure 4 The top three metabolic pathways in the middle dose group ( Figure 4 In the comparison of the high-dose group ( Figure 4 C) The top three metabolic pathways are tryptophan metabolism, niacin and nicotinamide metabolism, and alanine, aspartic acid and glutamate metabolism. It can be seen that in each dose group of fish bladder mucopolysaccharide, the metabolic pathways of alanine, aspartic acid and glutamate have very significant changes, which can be seen as the most important differential metabolic pathways for fish bladder mucopolysaccharide to resist arsenic toxicity. And after the action of fish bladder mucopolysaccharide, carbohydrate pathways such as pyruvate metabolism, glycolysis / gluconeogenesis and TCA cycle pathways have also changed, which is related to the inherent characteristics of fish bladder mucopolysaccharide. Amino acids can be divided into three categories: glucogenic amino acids, ketogenic amino acids and glucogenic and ketogenic amino acids. These amino acids will participate in the tricarboxylic acid cycle in different forms, thereby affecting the body's energy supply. From Example 1, it can be seen that arsenic exposure will cause energy imbalance due to vitamin metabolism disorders, and fish bladder mucopolysaccharide improves its imbalance by affecting amino acid metabolism. And the amino acid pathway will affect sugar metabolism and energy metabolism, and these changes will also affect the production of antioxidant glutathione, thereby affecting the oxidative balance system. Furthermore, the differential metabolites of alanine, aspartic acid and glutamate metabolism, the most critical metabolic pathways in the process of fish bladder mucopolysaccharide resistance to arsenic toxicity, were analyzed. The differential metabolites that changed in this metabolic pathway in the low-dose and high-dose groups were L-aspartic acid, D-aspartic acid and pyruvate. In the medium-dose group, in addition to the above metabolites, there were also L-glutamate and L-glutamine. Among them, L-aspartic acid was a differential metabolite that was significantly upregulated after the action of fish bladder mucopolysaccharide. Combined with KEGG analysis, it was found that L-aspartic acid was involved in 19 KEGG pathways. In addition to alanine, aspartic acid and glutamate metabolism in the key pathway changes, L-aspartic acid was also involved in histidine metabolism, arginine and proline metabolism. From the results of this part, it can be concluded that the metabolic markers of fish bladder mucopolysaccharide resistance to arsenic toxicity are L-aspartic acid, D-aspartic acid and pyruvate. The above data indicate that the screening of anti-arsenic toxicity metabolites of fish maw mucopolysaccharide provided by the present invention is rapid and efficient, and can provide a reference for the development of dietary supplements and drugs using fish maw mucopolysaccharide as an additive to alleviate arsenic toxicity, and the several metabolic markers of L-aspartic acid, D-aspartic acid and pyruvate obtained by screening the metabolic markers of anti-arsenic toxicity of fish maw mucopolysaccharide provided by the present invention can be used for subsequent exploration of anti-arsenic toxicity drug targets.
[0044] The embodiments described above are part of the embodiments of the present invention, but not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.
Claims
1. A metabolic marker of fish bladder mucopolysaccharide resistance to arsenic toxicity, characterized in that: The swim bladder mucopolysaccharide is a chondroitin sulfate A analogue containing a structural unit of →4GlcUAβ1→3GalNAc(4S)β1→ main chain; The arsenic toxicity is derived from the metabolic disorder induced by arsenic; The metabolic markers of the fish swim bladder mucopolysaccharide against arsenic toxicity include L-aspartic acid, D-aspartic acid and pyruvic acid.
2. The fish maw mucopolysaccharide metabolic marker for arsenic resistance according to claim 1, characterized in that: The biomarker of arsenic toxicity is at least one of taurine, thiamine, nicotinic acid mononucleotide compounds, and nicotinamide adenine dinucleotide.
3. A method for screening metabolic markers of fish maw mucopolysaccharide resistance to arsenic toxicity, characterized in that: include: The feces of mice subjected to arsenic-induced test after gavage with fish maw mucopolysaccharide were collected. After the feces were analyzed for differential metabolites by ultra-performance liquid chromatography-mass spectrometry, the metabolic pathways were assigned based on the differential metabolites and the metabolic markers of fish maw mucopolysaccharide against arsenic toxicity were analyzed.
4. The screening method according to claim 3, wherein The dosage of the fish swim bladder mucopolysaccharide for oral administration is 50-200 mg / kg.
5. The screening method according to claim 4, characterized in that The dosage of the fish swim bladder mucopolysaccharide administered orally is 100 mg / kg.
6. The screening method according to claim 3, wherein The differential metabolites include at least one of lipids, lipid-like substances, organic acids, and organic acid derivatives.
7. The screening method according to claim 3, characterized in that The metabolic pathway is a KEGG enriched pathway; The KEGG enrichment pathway is at least one of amino acids, carbohydrates, and lipids.
8. The screening method according to claim 7, characterized in that The key metabolic pathways were obtained by KEGG enrichment pathway analysis; The key metabolic pathway is at least one of alanine, aspartic acid, and glutamate.
9. Use of the fish swim bladder mucopolysaccharide anti-arsenic toxicity metabolic marker according to claim 1 in the preparation of a dietary supplement for preventing arsenic toxicity.
10. Use of the fish swim bladder mucopolysaccharide anti-arsenic toxicity metabolic marker according to claim 1 in preparing drug targets for improving arsenic poisoning.
Citation Information
Patent Citations
Application of swimming bladder-derived heparin mucopolysaccharide in preparing angiogenesis inhibitor
CN112107590A
Application of swim bladder glycosaminoglycan in preparation of intestinal injury medicine
CN117018020A
